Company: HROW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001641172-25-000925
Chunk: 2160

Company: HARROW, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 14
Chunk 2160
---
.2
     
    Indenture
    dated April 20, 2021, between Harrow, Inc. and U.S. Bank National Association, as Trustee (incorporated herein by reference to Exhibit
    4.1 to the Current Report on Form 8-K of Harrow, Inc. filed with the Securities and Exchange Commission on April 20, 2021).
  
    4.3
     
    First Supplemental
    Indenture dated April 20, 2021 between Harrow, Inc. and U.S. Bank National Association, as Trustee (incorporated herein by reference
    to Exhibit 4.2 to the Current Report on Form 8-K of Harrow, Inc. filed with the Securities and Exchange Commission on April 20, 2021).
  
    4.4
     
    Form
    of 8.625% Senior Note due 2026 (included as Exhibit A in Exhibit 4.3).
  
    4.5
     
    Second
    Supplemental Indenture dated December 20, 2022 between Harrow, Inc. and U.S. Bank Trust Company, National Association (incorporated
    herein by reference to Exhibit 4.2 to the Current Report on Form 8-K of Harrow, Inc. filed with the Securities and Exchange Commission
    on December 20, 2022).
  
    4.6
     
    Form
    of 11.875% Senior Note due 2027 (included as Exhibit A in Exhibit 4.5).
  
    10.1
     
    Form
    of Directors and Officers Indemnification Agreement (incorporated herein by reference to Exhibit 10.8 to the Current Report on Form
    8-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on September 21, 2007). 
  
    10.2#
     
    Imprimis
    Pharmaceuticals, Inc. Amended and Restated 2007 Stock Incentive and Awards Plan (incorporated herein by reference to Exhibit 10.3
    to the Quarterly Report on Form 10-Q of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on May 8,
    2013).

 70 

    10.3#
     
    Amendment
    No. 1 to Imprim